Drug Pipeline & Clinical Insights – November 2026
Explore recent approvals for HIBSAGO and Juvmo, with LucyRx clinical insights on treatment eligibility, safety monitoring, and pharmacy benefit costs.
Explore recent approvals for HIBSAGO and Juvmo, with LucyRx clinical insights on treatment eligibility, safety monitoring, and pharmacy benefit costs.
This month’s Drug Pipeline & Clinical Insights explores three new specialty therapies and what they could mean for pharmacy benefits, including cost, access, and appropriate use.